Please ensure Javascript is enabled for purposes of website accessibility

Teladoc Health Boosts Its Q1 Revenue Outlook Due to Surging Demand

By Keith Speights – Apr 14, 2020 at 5:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The COVID-19 pandemic is driving many new patients to use the telehealth leader's platform.

Teladoc Health (TDOC 4.84%) boosted its fiscal 2020 first-quarter revenue outlook on Tuesday to between $180 million and $181 million, up from its previous guidance for revenue between $169 million and $172 million. The company stated that the increase was based on "an unprecedented surge in demand" for its telehealth services due to the COVID-19 pandemic.

The number of virtual medical visits per day that Teladoc Health facilitates in the U.S. has more than doubled to above 20,000 since the first week of March. Teladoc said that more than 60% of those recent visits were from members who are new to its platform. Many Americans are under shelter-in-place orders and are turning to telehealth to seek medical care rather than visiting healthcare professionals in their offices or in hospitals, where they would be at higher risk of contracting COVID-19.

PC monitor with a physician holding a stethescope

Image source: Getty Images.

Based on the recent spike, Teladoc now expects to report that total visit volume during the first quarter, which ended March 31, rose to more than 1.8 million. That would be a 70% jump from the prior-year period.

Teladoc has implemented several initiatives to handle the surging demand for its telehealth services. It has streamlined the provider onboarding process to quickly add physicians. It has temporarily boosted physicians' pay in some cases. And it has also enhanced its visit queue algorithms to better serve patients.

While Teladoc's revenue will rise at least in the short term, so will its expenses. The company incurred additional costs of around $4 million related to its efforts to deal with higher patient volumes. Still, though, Teladoc now projects its Q1 adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) will land between $10 million and $11 million, with the lower end of the range up from its previous guidance of $9 million.

Keith Speights owns shares of Teladoc Health. The Motley Fool owns shares of and recommends Teladoc Health. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
$27.92 (4.84%) $1.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.